Human papillomavirus type 16 L1 virus-like particles (HPV16 L1 VLP)

Human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) are non-infectious, recombinant protein assemblies that mimic the outer shell of the HPV16 virion (National Cancer Institute, 2023). The L1 protein is the major capsid protein of the virus and has the intrinsic ability to self-assemble into VLPs that are morphologically identical to the actual virus but lack the oncogenic viral DNA (PubMed, PMID: 11544334). These particles are the central component of prophylactic vaccines such as Gardasil and Cervarix, which aim to prevent infection by high-risk HPV strains (FDA, 2020). HPV16 is a primary driver of cervical, anal, and oropharyngeal cancers, making it a critical target for public health interventions (WHO, 2022). When used as a vaccine antigen, the VLPs induce a potent immune response, specifically the production of neutralizing antibodies that prevent the virus from binding to and entering host epithelial cells (StatPearls, 2023). This blockade effectively prevents the establishment of chronic infection and the subsequent development of malignant lesions. The safety profile of these VLPs is well-established, with common side effects limited to minor injection site reactions and syncope (CDC, 2021).

Other names

HPV16 L1 proteinHuman papillomavirus type 16 major capsid proteinHPV16 VLPL1 capsid protein of HPV16

Induction of humoral immune response leading to the production of L1-specific neutralizing antibodies that prevent viral attachment and entry into host cells (CDC, 2021).